Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
Open Access
- 26 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-11
- https://doi.org/10.1038/s41598-021-84362-y
Abstract
We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean change of best corrected visual acuity (BCVA) at 24 months. Secondary outcomes were 36-month mean BCVA, mean central macular thickness (CMT) change, rates of eyes receiving supplementary intravitreal therapy, cataract surgery, intraocular pressure (IOP)-lowering drops and glaucoma surgery. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Nine real-world studies were included. The FAc implant yielded a significantly improved BCVA at 24 and 36 months (24-month MD = 4.52; 95% CI 2.56–6.48; 36-month MD = 8.10; 95% CI 6.34–9.86). These findings were comparable with the FAME study. The FAc implant yielded significantly reduced 24- and 36-month CMT. Pooled proportions of cataract surgery, IOP-lowering drops and glaucoma surgery were 39%, 27% and 3%, respectively, all lower than the FAME study. Pooled estimate of supplementary intravitreal therapy was 39%, higher than the 15.2% of the FAME study. This meta-analysis of real-world studies confirms favorable visual and anatomical outcomes following FAc insert for chronic DMO. In real-life studies more than one third of patients received supplementary intravitreal therapy, an issue that needs to be further explored.This publication has 34 references indexed in Scilit:
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaOphthalmology, 2016
- Systemic Safety of Prolonged Monthly Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular EdemaJAMA Ophthalmology, 2016
- Metaprop: a Stata command to perform meta-analysis of binomial dataArchives of Public Health, 2014
- Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular EdemaOphthalmology, 2014
- Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implantExpert Opinion on Pharmacotherapy, 2014
- Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular EdemaOphthalmology, 2012
- Long-term Benefit of Sustained-Delivery Fluocinolone Acetonide Vitreous Inserts for Diabetic Macular EdemaOphthalmology, 2011
- COMPARISON OF SPECTRAL/FOURIER DOMAIN OPTICAL COHERENCE TOMOGRAPHY INSTRUMENTS FOR ASSESSMENT OF NORMAL MACULAR THICKNESSRetina, 2010
- Assessing Risk of Bias in Included StudiesPublished by Wiley ,2008
- Normal Macular Thickness Measurements in Healthy Eyes Using Stratus Optical Coherence TomographyAmerican Journal of Ophthalmology, 2006